Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | LDHA | P00338 | 1/20 | 0.36 |
| ▸ | LDHB | P07195 | 1/20 | 0.36 |
| ▸ | NQO2 | P16083 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 3/20 | 0.36 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.35 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.35 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | TTR | P02766 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12290553 | 0.92 | TSHR (0.45) | TSHRALDH1A1OPRL1SMN1; SMN2CHRNB2 | |
| SCHEMBL11751246 | 0.92 | TSHR (0.45) | TSHRALDH1A1OPRL1SMN1; SMN2CHRNB2 | |
| SCHEMBL15994822 | 0.90 | TSHR (0.43) | TSHRALDH1A1OPRL1SMN1; SMN2CHRNB2 | |
| SCHEMBL23215227 | 0.87 | QDPR (0.43) | TSHRALDH1A1CHRNB2CHRNA4 | |
| SCHEMBL29768397 | 0.87 | QDPR (0.43) | TSHRALDH1A1CHRNB2CHRNA4 | |
| SCHEMBL10387633 | 0.84 | OPRL1 (0.49) | TSHRALDH1A1OPRL1SMN1; SMN2LDHA | |
| SCHEMBL6152672 | 0.76 | CHRNB2 (0.58) | ALDH1A1SMN1; SMN2CHRNB2CHRNA4KDM4E | |
| SCHEMBL4965472 | 0.76 | CHRNB2 (0.58) | ALDH1A1SMN1; SMN2CHRNB2CHRNA4KDM4E | |
| SCHEMBL3785910 | 0.76 | SMN1; SMN2 (0.41) | ALDH1A1OPRL1SMN1; SMN2ACHE | |
| SCHEMBL12290554 | 0.75 | SMN1; SMN2 (0.48) | TSHRALDH1A1OPRL1SMN1; SMN2LDHA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108026077-A | PHENOXYMETHYL DERIVATIVES | 豪夫迈·罗氏有限公司 | 2018-05-11 | — | — | CN | disclosed |
| EP-2358716-B1 | INHIBITORS OF FATTY ACID BINDING PROTEIN (FABP) | MERCK SHARP & DOHME (US) | 2016-01-06 | — | — | EP | disclosed |
| US-8815875-B2 | Inhibitors of fatty acid binding protein (FABP) | MERCK SHARP & DOHME CORP. (US) | 2014-08-26 | — | — | US | disclosed |
| US-8815875-B2 | Inhibitors of fatty acid binding protein (FABP) | MERCK SHARP & DOHME CORP. (US) | 2014-08-26 | — | — | US | disclosed |
| US-20110237575-A1 | INHIBITORS OF FATTY ACID BINDING PROTEIN (FABP) | MERCK SHARP & DOHME LLC | 2011-09-29 | — | — | US | disclosed |
| US-20110237575-A1 | INHIBITORS OF FATTY ACID BINDING PROTEIN (FABP) | MERCK SHARP & DOHME LLC | 2011-09-29 | — | — | US | disclosed |
| WO-2010056631-A1 | INHIBITORS OF FATTY ACID BINDING PROTEIN (FABP) | SCHERING CORPORATION (US) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237575-A1 | INHIBITORS OF FATTY ACID BINDING PROTEIN (FABP) | FABP4, FABP1, FABP3 | TSHR 2940/4885ALDH1A1 781/4885OPRL1 799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.